Orepaxam: Withdrawal of the marketing authorisation application

treprostinil diolamine


Ferrer Internacional S.A. withdrew its application for a marketing authorisation of Orepaxam for the treatment of pulmonary arterial hypertension.

The company withdrew the application on 11 October 2022.

Key facts

Product number
International non-proprietary name (INN) or common name
  • treprostinil diolamine
Active substance
  • treprostinil diolamine
Date of withdrawal
Company making the application
Ferrer Internacional S.A.
Withdrawal type
Initial authorisation

Related information on withdrawals

A question-and-answer (Q&A) document provides a summary of the CHMP's evaluation of the medicine at the time of the withdrawal of the application, and includes a link to the company's formal withdrawal letter.

An assessment report is published when the application is withdrawn after the first stage of the CHMP's evaluation is completed ('day 120').

How useful was this page?

Add your rating